Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 322

1.

Inhibition of polo-like kinase 1 promotes hyperthermia sensitivity via inactivation of heat shock transcription factor 1 in human retinoblastoma cells.

Yunoki T, Tabuchi Y, Hayashi A, Kondo T.

Invest Ophthalmol Vis Sci. 2013 Dec 23;54(13):8353-63. doi: 10.1167/iovs.13-12618.

PMID:
24366665
2.

BAG3 protects against hyperthermic stress by modulating NF-κB and ERK activities in human retinoblastoma cells.

Yunoki T, Tabuchi Y, Hayashi A, Kondo T.

Graefes Arch Clin Exp Ophthalmol. 2015 Mar;253(3):399-407. doi: 10.1007/s00417-014-2874-1. Epub 2014 Dec 4.

PMID:
25471019
3.

Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.

Schwermer M, Dreesmann S, Eggert A, Althoff K, Steenpass L, Schramm A, Schulte JH, Temming P.

Clin Exp Ophthalmol. 2017 Apr;45(3):288-296. doi: 10.1111/ceo.12838. Epub 2016 Nov 10.

PMID:
27647547
5.

Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.

Zhang Y, Du XL, Wang CJ, Lin DC, Ruan X, Feng YB, Huo YQ, Peng H, Cui JL, Zhang TT, Wang YQ, Zhang H, Zhan QM, Wang MR.

Gastroenterology. 2012 Mar;142(3):521-530.e3. doi: 10.1053/j.gastro.2011.11.023. Epub 2011 Nov 19.

PMID:
22108192
6.

The antitumor effect of PLK1 and HSF1 double knockdown on human oral carcinoma cells.

Kim SA, Kwon SM, Yoon JH, Ahn SG.

Int J Oncol. 2010 Apr;36(4):867-72.

PMID:
20198330
8.

Inhibition of heat shock protein response enhances PS-341-mediated glioma cell death.

Liu Y, Zheng T, Zhao S, Liu H, Han D, Zhen Y, Xu D, Wang Y, Yang H, Zhang G, Wang C, Wu J, Ye Y.

Ann Surg Oncol. 2012 Jul;19 Suppl 3:S421-9. doi: 10.1245/s10434-011-1881-2. Epub 2011 Jul 6.

PMID:
21732139
9.

Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells.

Harris PS, Venkataraman S, Alimova I, Birks DK, Donson AM, Knipstein J, Dubuc A, Taylor MD, Handler MH, Foreman NK, Vibhakar R.

BMC Cancer. 2012 Mar 5;12:80. doi: 10.1186/1471-2407-12-80.

10.

Polo-like kinase 1 phosphorylates heat shock transcription factor 1 and mediates its nuclear translocation during heat stress.

Kim SA, Yoon JH, Lee SH, Ahn SG.

J Biol Chem. 2005 Apr 1;280(13):12653-7. Epub 2005 Jan 20.

11.

Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells.

Bu Y, Yang Z, Li Q, Song F.

Oncology. 2008;74(3-4):198-206. doi: 10.1159/000151367. Epub 2008 Aug 20.

PMID:
18714168
12.

Polo-like kinase 1 inhibition as a new therapeutic modality in therapy of cholangiocarcinoma.

Thrum S, Lorenz J, Mössner J, Wiedmann M.

Anticancer Res. 2011 Oct;31(10):3289-99.

PMID:
21965739
13.

Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.

Liu X, Choy E, Harmon D, Yang S, Yang C, Mankin H, Hornicek FJ, Duan Z.

Anticancer Drugs. 2011 Jun;22(5):444-53. doi: 10.1097/CAD.0b013e32834513f4.

PMID:
21399492
15.

Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.

Nihal M, Stutz N, Schmit T, Ahmad N, Wood GS.

Cell Cycle. 2011 Apr 15;10(8):1303-11. Epub 2011 Apr 15.

PMID:
21436619
16.

c-Jun N-terminal kinase is involved in the regulation of proliferation and apoptosis by integrin-linked kinase in human retinoblastoma cells.

Chen Z, Yang A, Xu C, Xing Y, Gong W, Li J.

Graefes Arch Clin Exp Ophthalmol. 2011 Sep;249(9):1399-407. doi: 10.1007/s00417-010-1607-3. Epub 2011 Jan 14.

PMID:
21234586
17.

Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.

Peter B, Gleixner KV, Cerny-Reiterer S, Herrmann H, Winter V, Hadzijusufovic E, Ferenc V, Schuch K, Mirkina I, Horny HP, Pickl WF, Müllauer L, Willmann M, Valent P.

Haematologica. 2011 May;96(5):672-80. doi: 10.3324/haematol.2010.031328. Epub 2011 Jan 17.

18.

Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.

Lee C, Fotovati A, Triscott J, Chen J, Venugopal C, Singhal A, Dunham C, Kerr JM, Verreault M, Yip S, Wakimoto H, Jones C, Jayanthan A, Narendran A, Singh SK, Dunn SE.

Stem Cells. 2012 Jun;30(6):1064-75. doi: 10.1002/stem.1081.

19.

Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.

Xu WJ, Zhang S, Yang Y, Zhang N, Wang W, Liu SY, Tian HW, Dai L, Xie Q, Zhao X, Wei YQ, Deng HX.

Cancer Biother Radiopharm. 2011 Aug;26(4):427-36. doi: 10.1089/cbr.2010.0922. Epub 2011 Jul 28.

PMID:
21797676
20.

Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.

Mok WC, Wasser S, Tan T, Lim SG.

World J Gastroenterol. 2012 Jul 21;18(27):3527-36. doi: 10.3748/wjg.v18.i27.3527.

Supplemental Content

Support Center